Drugs / ATTR-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06977737 | Mar 2025 → Dec 2029 expected | cancer | Accession Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-30 | Accession Therapeutics Limited | Regulatory Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK accessiontherapeutics.com ↗
Following clinical scientific advice through the European Medicines Agency, the company has also submitted a clinical trial application in Spain where there is significant expertise in the treatment of carcinomas. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Accession Therapeutics Limited | Accession Therapeutics awarded €7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy accessiontherapeutics.com ↗ |
| 2025-11-17 | Accession Therapeutics Limited | Accession Therapeutics doses first patient in Phase 1 clinical trial of TROCEPT-01 (ATTR-01), a novel cancer immunotherapy accessiontherapeutics.com ↗ |
| 2025-01-30 | Accession Therapeutics Limited | Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK accessiontherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATTR-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06977737 ↗ |
| Route | Intravenous | “Intravenous injection” NCT06977737 ↗ |